Diagnostic Center | May 20, 2023
Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The partnership will capitalize on the combined capabilities of the two organizations
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Fully equipped labs with 75-member team set-up and made operational in <100 days
From cancer research to diagnostic solutions
The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Subscribe To Our Newsletter & Stay Updated
